<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053701</url>
  </required_header>
  <id_info>
    <org_study_id>1210M23141</org_study_id>
    <secondary_id>P41EB015894</secondary_id>
    <nct_id>NCT02053701</nct_id>
  </id_info>
  <brief_title>High-field Brain Magnetic Resonance Spectroscopy</brief_title>
  <official_title>Technical Developments for High-field Brain Magnetic Resonance Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Biomedical Imaging and Bioengineering (NIBIB)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic resonance spectroscopy (MRS) allows non-invasive measurement of the concentration of&#xD;
      up to 18 metabolites in the brain (&quot;neurochemical profile&quot;).&#xD;
&#xD;
      The objective of this proposal is to develop new methods for high-field brain MRS (3 to 7&#xD;
      Tesla).&#xD;
&#xD;
      Our main hypothesis is that higher magnetic fields lead to improved spatial and temporal&#xD;
      resolution and improved quantification precision.&#xD;
&#xD;
      Aims&#xD;
&#xD;
        1. To obtain improved &quot;neurochemical profiles&quot; in the brain using single voxel proton MRS&#xD;
           at very high field (3 Tesla to 7 Tesla).&#xD;
&#xD;
        2. To develop new methods for proton magnetic resonance spectroscopic imaging (MRSI) to&#xD;
           obtain metabolic maps at very high field (3 Tesla to 7 Tesla).&#xD;
&#xD;
      Since this project is focused on technical development, only healthy volunteers will be&#xD;
      recruited (no patients).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2010</start_date>
  <completion_date type="Anticipated">November 2030</completion_date>
  <primary_completion_date type="Anticipated">November 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Precision of quantification of brain metabolites concentrations</measure>
    <time_frame>One time only</time_frame>
    <description>This protocol is devoted exclusively to technical development and testing of MRS methods on our MR scanners. As such, there is no well-defined outcome measure or time frame. It is a continuous effort. We recruit subjects on an ongoing basis to test, optimize, and assess the performance of newly developed techniques.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no metallic implant or other MRI-incompatible device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Gilles Henry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Magnetic Resonance Research, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Magnetic Resonance Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>quantification precision</keyword>
  <keyword>brain</keyword>
  <keyword>brain metabolites</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

